Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: A review

International Journal of COPD

Volumn 8, Issue , 2013, Pages 425-432

  Ridolo, Erminia ^a   Montagni, Marcello ^a   Olivieri, Elisa ^a   Riario Sforza, Gian Galeazzo ^b   Incorvaia, Cristoforo ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b ICP Hospital   (Italy)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; Very long acting 2 agonists

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARMOTEROL; FLUTICASONE FUROATE; FORMOTEROL; INDACATEROL; LONG ACTING DRUG; OLODATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; UMECLIDINIUM; VILANTEROL; VILANTEROL TRIFENATATE;

ASTHMA; BINDING AFFINITY; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; COUGHING; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; LUNG FUNCTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); QT INTERVAL; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TREATMENT DURATION; TREMOR; UNSPECIFIED SIDE EFFECT;

BRONCHODILATORS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; VERY LONG-ACTING Β2-AGONISTS;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; HUMANS; INDANS; LUNG; MEDICATION ADHERENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84884603810     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S49179     Document Type: Review

References (42)

1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187: 347-365.
2. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149-163.
3. Keating GM. Tiotropium bromide inhalation power: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012;72:273-300.
4. Cazzola M, Page CP, Rogliani P, Matera MG. β2-agonists therapy in lung disease. Am J Respir Crit Care Med. 2013;187:690-696.
5. Beeh KM, Beier J. The short, the long, and the ultra-long: why dura-tion of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther. 2010;27:150-159.
6. Malerba M, Radaeli A, Morjaria JB. Therapeutic potential for novel ultra long acting beta2-agonists in the management of COPD: biological and pharmacological aspects. Drug Discov Today. 2012;17:496-504.
7. Cecere LM, Slatore CG, Uman JE, et al. Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD). COPD. 2012;9:251-258.
8. Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstruc-tive pulmonary disease (COPD): strengths and limitations. Respir Res. 2010;11:79-85.
9. Barnes P, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive and seamless design. Pulm Pharmacol. 2010;23:165-171.
10. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B; INDORSE Study Investigators. Long-term safety and efficacy of indacaterol, a long-acting beta2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140:68-75.
11. Feldman G, Siler T, Prasad N, et al; INLIGHT Study Group. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10: 11-20.
12. O'Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D; The INABLE Study Group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105:1030-1036.
13. Kornmann O, Dahl R, Centanni S, et al; The INLIGHT-2 Study Investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37: 273-279.
14. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C; INSIST Study Group. Indacaterol once-daily provides superior efficacy to salme-terol twice-daily in COPD: a 12-week study. Respir Med. 2011;105: 719-726.
15. Laforce C, Aumann J, Parreno LD, Iqbal A, Young D, Owen R; INTEGRAL Study Investigators. Sustained 24-hour efficacy of once-daily indacaterol (300 μg) in patients with chronic obstructive pulmo-nary disease: a randomized, cross-over study. Pulm Pharmacol Ther. 2011;24:162-168.
16. Dahl R, Chung KF, Buhl R, et al; INVOLVE Study Investigators. Efficacy of a new once-daily inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473-479.
17. Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M; INTIME Study Investigators. Indacaterol provides 24-hour bronchodila-tion in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res. 2010;11:135-139.
18. Donohue JF, Fogarty C, Lotvall J, et al; INHANCE study investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182: 155-162.
19. Buhl R, Dunn LJ, Disdier C, et al; INTENSITY Study Group. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38:797-803.
20. Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:477-492.
21. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of inda-caterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008;102:1033-1044.
22. Khindri S, Sabo R, Harris S, Woessner R, Jennings S, Drollmann AF. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med. 2011;11:31.
23. Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio- and cerebro-vascular safety of indacaterol versus formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105:571-579.
24. Pascoe S, Reynolds C, Pleskow W, et al. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol Ther. 2011;49:153-161.
25. Cutler DM, Everett W. Thinking outside the pillbox - medication adherence as a priority for health care reform. N Engl J Med. 2010;362: 1553-1555.
26. Jones PW, Barnes N, Vogelmeier C, Lawrence D, Kramer B. Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J. 2011;20:380-388.
27. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63: 831-838.
28. Incorvaia C, Riario-Sforza GG. Effect of patient education on adher-ence to drug treatment for chronic obstructive pulmonary disease. Ann Thorac Med. 2011;6:242-243.
29. Ribeiro M, Chapman KR. Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2012;7:145-152.
30. Procopiou PA, Barrett VJ, Bevan NJ, et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010;53:4522-4530.
31. Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142:119-127.
32. Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PloS One. 2012;7:e50716.
33. Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med. 2013;107:560-569.
34. Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med. 2013;107:550-559.
35. Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characteriza-tion of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334:53-62.
36. Casarosa P, Kolak I, Kiechle T, et al. Functional and biochemical ratio-nales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337:600-609.
37. van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel 2-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24:666-672.
38. Kikkawa H, Isogaya M, Nagao T, Kurose H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. Mol Pharmacol. 1998;53:128-134.
39. Rosethorne EM, Turner RJ, Fairhurst RA, Charlton SJ. Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol. 2010;382:255-263.
40. Voss HP, Shukrula S, Wu TS, Donnel D, Bast A. A functional beta-2 adrenoceptor-mediated chronotropic response in isolated guinea pig heart tissue: selectivity of the potent beta-2 adrenoceptor agonist TA 2005. J Pharmacol Exp Ther. 1994;271:386-389.
41. Bateman ED. Carmoterol - safety and tolerability of a long-acting β2 agonist in patients with COPD. Proc Am Thorac Soc. 2008;5:A653.
42. Vogelmeier C, Magnussen H, LaForce C, Owen R, Kramer B. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist inda-caterol against established treatments in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2011;5:345-357.